Otsuka said to eye $300M deal for Claris injectables; Eisai sues insurer over whistleblower claim;

@FiercePharma: Pfizer slashes Viagra prices in Canada to compete with new generics. Cut = 25%. News | Follow @FiercePharma

> Claris Lifesciences is said to be in talks to sell its injectables business to Japan-based Otsuka Pharma for up to $300 million. Report

> Eisai has sued Zurich American Insurance for denying a claim stemming from a whistleblower lawsuit field by a former sales rep. Report

> Hetero India and Neopharma's joint venture, Nexgen Pharma, plans to sell branded generics in the United Arab Emirates, aiming for 100 products by 2016. Report

> Oregon Health & Science University School of Medicine plans to recommend that researchers no longer accept speaking fees from drugmakers. Report

> India's Lupin launched its version of the Abbott Laboratories' ($ABT) cholesterol pill Tricor. Report

> The American Academy of Pediatrics recommended that doctors routinely prescribe "morning after" contraception to teens in case they need it; the drugs aren't available over the counter to patients under 17. Report

Medical Device News

 @FierceMedDev: Illumina gains legal means to keep fighting a patent claim against Complete Genomics. News | Follow @FierceMedDev

 @MarkHFierce: Volcano Corp., a rumored acquisition target, has itself acquired a company. More | Follow @MarkHFierce

 @DamianFierce: Innovent Biologics is moving into WuXi PharmaTech's backyard with a new Chinese plant. Report | Follow @DamianFierce

> Sorin commits $5.4M to percutaneous mitral valve replacement startup. Article

> Report: Baxter close to paying $4B for dialysis rival Gambro. More

> Analyst: St. Jude's woe is good news for Boston Scientific. News

Biotech News

 @FierceBiotech: Trending on Blockbuster buzz: 15 top therapies in late-stage development. Special Report | Follow @FierceBiotech

 @JohnCFierce: AstraZeneca, Pfizer partner on $100M drug research collaboration project. Report | Follow @JohnCFierce

 @RyanMFierce: Averting the next bapi bust? J&J exec prescribes new approach to Alzheimer's drug development. Story | Follow @RyanMFierce

> J&J preps case for quick FDA approval of new TB drug. News

> No, Minister: Disgruntled Novartis threatens to steer R&D away from U.K. Story

Biotech IT News

> Eisai's H3 Bio leans on bioinformatics as cancer researcher expands. Report

> NIH taps Northrop Grumman for $30M bioinformatics project. Article

> J&J exec prescribes adaptive approach to Alzheimer's drug development. Story

CRO News

> U.K. wants CRO input on clinical trial reforms. Report

> QPS boosts Phase I capabilities in Netherlands. News

> Innovent targets WuXi with biologics plan. Story

> ShangPharma stumbles over increased costs in Q3. Article

And Finally... Ritalin and other stimulant drugs cut the crime rate in adults with ADHD, a study found. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.